Cost-Effectiveness of Eml4-Alk Gene Targeted First-Line Ceritinib Treatment Among Patients With Advanced Alk-Positive Non–Small Cell Lung Cancer
May 1, 2015, 00:00
10.1016/j.jval.2015.03.1177
https://www.valueinhealthjournal.com/article/S1098-3015(15)01234-6/fulltext
Title :
Cost-Effectiveness of Eml4-Alk Gene Targeted First-Line Ceritinib Treatment Among Patients With Advanced Alk-Positive Non–Small Cell Lung Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01234-6&doi=10.1016/j.jval.2015.03.1177
First page :
A203
Section Title :
Cancer
Open access? :
No
Section Order :
639